Harvard Bioscience (HBIO) Short-Term Debt issuances (2021 - 2024)

Harvard Bioscience (HBIO) has 4 years of Short-Term Debt issuances data on file, last reported at $3.2 million in Q3 2024.

• Quarterly Short-Term Debt issuances rose 225.0% year-over-year to $3.2 million in Q3 2024, while the trailing twelve-month figure through Jun 2025 was $3.2 million (down 56.95% YoY) and the FY2024 annual result came in at $8.8 million, up 95.56% from the prior year.
• Short-Term Debt issuances climbed to $3.2 million in Q3 2024 per HBIO's latest filing, from $3.0 million in the prior quarter.
• Across five years, Short-Term Debt issuances topped out at $3.8 million in Q2 2022 and bottomed at $1.0 million in Q2 2023.
• The 4-year median for Short-Term Debt issuances is $2.1 million (2021), against an average of $2.1 million.
• The widest annual swing landed in 2023, when Short-Term Debt issuances plunged 73.68%; it then jumped 225.0% in 2024.
• Tracing HBIO's Short-Term Debt issuances over 4 years: stood at $1.8 million in 2021, then jumped by 42.86% to $2.5 million in 2022, then tumbled by 60.0% to $1.0 million in 2023, then jumped by 225.0% to $3.2 million in 2024.
• Per Business Quant, the three latest HBIO Short-Term Debt issuances figures stand at $3.2 million (Q3 2024), $3.0 million (Q2 2024), and $2.5 million (Q1 2024).

Peer Comparison